The trading price of PTC Therapeutics Inc (NASDAQ:PTCT) closed lower on current market day and closing at $57.03, -0.19% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $56.16 and $57.97. In examining the 52-week price action we see that the stock hit a 52-week high of $58.38 and a 52-week low of $24.00. Over the past month, the stock has gained 12.51% in value.
PTC Therapeutics Inc, whose market valuation is $4.50 billion at the time of this writing, is expected to release its quarterly earnings report on 2025-Feb-26. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -0.79 per share this quarter, however they have predicted annual earnings per share of -3.43 for current year and -1.83 for next year.
Analysts have forecast the company to bring in revenue of 437.16M for the current quarter, with the likely lows of 149.2M and highs of 1.18B. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 955.37M.
On the technical side, indicators suggest PTCT has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned PTCT a recommendation rating is 7. Out of them, 3 rate it a Hold, while 2 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged PTC Therapeutics Inc (PTCT) as Underweight, while 2 advise Sell. Analysts have rated the stock Hold, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that PTCT’s price is currently 6.05% off the SMA20 and 14.31% off the SMA50. The RSI metric on the 14-day chart is currently showing 65.06, and weekly volatility stands at 3.34%. When measured over the past 30 days, the indicator reaches 5.28%. PTC Therapeutics Inc (NASDAQ:PTCT)’s beta value is currently sitting at 0.52, while the Average True Range indicator is currently displaying 2.39. With analysts defining $45-$58 as the low and high price targets, we arrive at a consensus price target of $52 for the trailing 12-month period. The current price is about 21.09% off the estimated low and -1.7% off the forecast high, based on this estimate. Investors will be thrilled if PTCT’s share price rises to $52, which is the median consensus price. At that level, PTCT’s share price would be 8.82% above current price.
To see how PTC Therapeutics Inc stock has been performing in comparison to its peers in the industry, here are the numbers: PTCT stock’s performance was -0.19% in the latest trading, and 93.26% in the past year.
An evaluation of the daily trading volume of PTC Therapeutics Inc (NASDAQ:PTCT) indicates that the 3-month average is 714.44K. However, this figure has increased over the past 10 days to an average of 0.78.
Currently, records show that 77.70 million of the company’s shares remain outstanding. The insiders hold 2.60% of outstanding shares, whereas institutions hold 97.64%. The stats also highlight that short interest as of 2025-02-28, stood at 3.79 million shares, resulting in a short ratio of 4.91 at that time. From this, we can conclude that short interest is 738.00 of the company’s total outstanding shares. It is noteworthy that short shares in February were down slightly from the previous month’s figure, which was 4.16 million. However, since the stock’s price has seen 26.34% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
